JACC:终晚期支架血栓形成的机制研究

2017-11-01 MedSci MedSci原创

终晚期支架血栓形成(VLScT)在生物可吸收支架植入术后患者中比涂层金属支架植入的发生率更高,本研究的目的旨在利用光学相干断层扫描(OCT)技术探索VLScT的形成机制。本研究纳入了2013年至2017年在19个医疗中心诊断为VLSct的36例患者,VLSct出现的平均时间为术后20个月,VLSct出现后,有83%的患者接受了阿司匹林单一治疗,17%的患者接受了双重抗血小板治疗。VLSct出现的原

终晚期支架血栓形成(VLScT)在生物可吸收支架植入术后患者中比涂层金属支架植入的发生率更高,本研究的目的旨在利用光学相干断层扫描(OCT)技术探索VLScT的形成机制。本研究纳入了2013年至2017年在19个医疗中心诊断为VLSct的36例患者,VLSct出现的平均时间为术后20个月,VLSct出现后,有83%的患者接受了阿司匹林单一治疗,17%的患者接受了双重抗血小板治疗。VLSct出现的原因包括支架不连续性(42.1%)、支架异位(18.4%)、新发动脉粥样硬化(18.4%)、支架回缩(10.5%)和边缘相关的疾病进展(2.6%)。支架的不连续性([OR]: 110; 95% [CI]: 73.5 - 173; p < 0.001)和错位(OR: 17.0; 95% CI: 14.8 - 19.7; p < 0.001)在血栓的支架区域更常见。研究结果显示,导致终晚期支架血栓形成最常见的原因就是支架的不连续性,提示支架吸收不良。原始出处:Kyohei Y et al.Mechanisms of Very Late Bioresorbable Scaffold Thr

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056171, encodeId=68e220561e17f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 30 18:06:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853833, encodeId=a50f185383377, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Dec 22 11:06:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325589, encodeId=5fb0132558928, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582574, encodeId=aa3115825e4f1, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257872, encodeId=49be25e872ca, content=这是临床文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Nov 01 20:15:48 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056171, encodeId=68e220561e17f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 30 18:06:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853833, encodeId=a50f185383377, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Dec 22 11:06:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325589, encodeId=5fb0132558928, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582574, encodeId=aa3115825e4f1, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257872, encodeId=49be25e872ca, content=这是临床文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Nov 01 20:15:48 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2017-12-22 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056171, encodeId=68e220561e17f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 30 18:06:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853833, encodeId=a50f185383377, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Dec 22 11:06:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325589, encodeId=5fb0132558928, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582574, encodeId=aa3115825e4f1, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257872, encodeId=49be25e872ca, content=这是临床文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Nov 01 20:15:48 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056171, encodeId=68e220561e17f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 30 18:06:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853833, encodeId=a50f185383377, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Dec 22 11:06:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325589, encodeId=5fb0132558928, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582574, encodeId=aa3115825e4f1, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257872, encodeId=49be25e872ca, content=这是临床文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Nov 01 20:15:48 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056171, encodeId=68e220561e17f, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Mar 30 18:06:00 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853833, encodeId=a50f185383377, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Dec 22 11:06:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325589, encodeId=5fb0132558928, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1582574, encodeId=aa3115825e4f1, content=<a href='/topic/show?id=c1695e118ac' target=_blank style='color:#2F92EE;'>#支架血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57118, encryptionId=c1695e118ac, topicName=支架血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b83016955660, createdName=ms1779634646866130, createdTime=Fri Nov 03 08:06:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257872, encodeId=49be25e872ca, content=这是临床文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Nov 01 20:15:48 CST 2017, time=2017-11-01, status=1, ipAttribution=)]
    2017-11-01 lovetcm

    这是临床文章

    0

相关资讯

HEART:易感基因突变的静脉血栓患者出血风险更高

本研究的目的旨在评估基因变异是否能识别静脉血栓栓塞(VTE)患者华法林增加出血的风险。本次多中心随机双盲研究评估依度沙班和华法林治疗最开始接受肝素治疗的VTE患者的有效性和安全性。在亚分析组中,将CYP2C9 和 VKORC1基因有变异的患者随机分成三个华法林治疗组(正常、敏感和高度敏感)。最终,本研究共纳入3956名患者,在1978名随机分配至华法林治疗组的患者中,63%患者为正常反应组,34.

JACC:二尖瓣修复术的预后研究

对于美国FDA批准通过的设备,上市后监督其有效性和安全性是必要的。本研究的目的旨在评估治疗二尖瓣反流的二尖瓣换瓣的有效性和安全性。本研究纳入分析了胸外科学会/美国心脏病学会导管治疗注册中心的二尖瓣换瓣病人的临床数据,包括2013年至2015年在145家医院接受治疗的2952名患者,其中纳入分析的有1827名患者。平均年龄为82岁(男性占55.8%),胸外科学会预测二尖瓣修复和置换的平均死亡率分别为

JACC:全面阐述心血管病预防:零级、一级、二级和三级预防,战线应前移

近期JACC杂志全面阐述了心血管病的预防策略和血糖、血脂、血压的控制目标。

JAHA:血清胆碱代谢物可预测心血管疾病风险

目前,关于血清甜菜碱浓度、胆碱代谢和主要心血管事件(CVD)发生的风险尚未阐明。本研究的目的旨在评估胆碱通路代谢与CVD发生风险的相关性。本研究纳入了229例CVD患者和751例随机选择的研究对象,采用液相色谱串联质谱法测定所有研究对象在基线和随访1年后,在胆碱通路5种代谢物的血浆浓度:三甲胺氮氧化物、甜菜碱、胆碱、磷酸胆碱和α‐甘油磷酸胆碱。经过4.8年时间的随访,每升高1-SD的胆碱和α‐甘油

J Am Acad Dermatol:住院儿童中,银屑病与多种心血管并发症风险增高相关

背景:银屑病已被证明与成年人的心血管疾病有关。但银屑病对儿童心血管风险的影响却鲜为人知。目的:本研究旨在确定儿童银屑病与心血管并发症是否存在相关性。方法:本研究的数据来自2002-2012年韩国全国住院患者样本,研究人员对其中4884448例年龄在0-17岁的住院儿童的数据进行了分析。研究人员建立了双变量和多变量的logistic回归模型来计算银屑病儿童患心血管并发症的几率。结果:在多元logis

CIRC RES:研究揭示导致心血管疾病与死亡的一种风险激素!

美国心脏协会杂志“循环研究”的新研究显示,甲状腺激素(称为FT4)高出正常水平,与老年人和中年人的动脉疾病和死亡有关。